The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- C-peptide
研究概览
简要总结
This study will investigate if the effect of DPP-4 inhibitors is mediated in part by Glucose-dependent insulinotropic polypeptide.
详细描述
A randomized, placebo controlled study. Using a GIP receptor antagonist, we will investigate the glucose lowering effect of GIP during treatment with DPP-4 inhibitors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
盲法说明
Double blinded study. Both participants and investigators are blinded to interventions.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •type 2 diabetes, treatment: lifestyle changes or metformin
- •HbA1c < 75 mmol/mol
排除标准
- •diagnosed liver disease
- •eGFR < 60 ml/min/1,73m2
- •NYHA III or IV
研究组 & 干预措施
Placebo
Placebo tablet for placebo treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
干预措施: Placebo (Other)
Placebo
Placebo tablet for placebo treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
干预措施: GIP receptor antagonist (Other)
Placebo
Placebo tablet for placebo treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
干预措施: Placebo tablet (Other)
DPP-4 inhibitor
DPP-4 inhibitor treatment for active treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
干预措施: Placebo (Other)
DPP-4 inhibitor
DPP-4 inhibitor treatment for active treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
干预措施: GIP receptor antagonist (Other)
DPP-4 inhibitor
DPP-4 inhibitor treatment for active treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
干预措施: DPP-4 inhibitor (Drug)
结局指标
主要结局
C-peptide
时间窗: 5 hours
Concentrations of C-peptide during GIP receptor antagonism compared to placebo
次要结局
- Total and intact GIP(5 hours)
- Insulin(5 hours)
- Total and intact GLP-1(5 hours)
- CTX(5 hours)
- Plasma glucose(5 hours)
- Glucagon(5 hours)
- Lipids(5 hours)
研究者
Signe Stensen
MD
University Hospital, Gentofte, Copenhagen